Huma Q. Rana, MD, MPH, an assistant professor of medicine at Dana-Farber Cancer Institute and the clinical director of Cancer Genetics and Prevention at Harvard Medical School, discusses the prevalence of pathogenic variants in patients with prostate cancer enrolled on the ProGen study.
Website: www.onclive.com
Twitter: / onclive
Facebook: / onclive
LinkedIn: / onclive